ALEMBIC PHARMA share price has plunged 5% and is presently trading at Rs 1,181.9.
Meanwhile, the BSE HEALTHCARE index is at 43,227.3 (down 0.8%).
Among the top losers in the BSE HEALTHCARE index today are GSK Pharma (down 4.2%) and Jubilant Pharmova (down 3.9%).
ASTRAZENECA PHARMA (up 7.2%) and Natco Pharma (up 1.4%) are among the top gainers today.
Over the last one year, ALEMBIC PHARMA has moved up from Rs 790.9 to Rs 1,181.9, registering a gain of Rs 391.0 (up 49.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,227.3, registering a gain of 52.1% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 146.1%), SUVEN PHARMACEUTICALS (up 101.3%) and Glenmark Pharma (up 98.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,726.4 .
The top gainers among the BSE Sensex today are ITC (up 1.7%) and ICICI Bank (up 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Bharti Airtel.
In the meantime, NSE Nifty is at 24,972.4 (down 0.2%). MUNDRA PORT & SEZ and ONGC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 81,726.4, registering a gain of 16,214.3 points (up 24.8%).
ALEMBIC PHARMA net profit grew 11.3% YoY to Rs 1,342 million for the quarter ended June 2024, compared to a profit of Rs 1,206 million a year ago. Net sales rose 5.1% to Rs 15,617 million during the period as against Rs 14,862 million in April-June 2023.
For the year ended March 2024, ALEMBIC PHARMA reported 80.1% increase in net profit to Rs 6,158 million compared to net profit of Rs 3,420 million during FY23. Revenue of the company grew 10.2% to Rs 62,286 million during FY24.
The current Price to earnings ratio of ALEMBIC PHARMA, based on rolling 12 month earnings, stands at 36.9.
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Plunges 5%; BSE HEALTHCARE Index Down 0.8%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!